Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
Clinical trial NCT04722640 · UNKNOWN
Trial details
- NCT number
- NCT04722640
- Sponsor
- Istituto Clinico Humanitas
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-25
- Primary completion
- 2022-01-31
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.